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Despite the proven benefits of thrombolytic thera 
py in acute myocardial infarction, concern for its 
complicationq especially in patients misdiag- 
nosed with myocardial infarction, has led to hesi- 
tancy in its use. Historical, clinical and electro- 
cardiographic criteria were developed for enrolling 
patients with suspected acute myocardial infarc- 
tion into thrombolytic trials by noncardiovascular 
specialists. The incidence of misdiagnosis of my- 
ocardial infarction and the clinical outcomes when 
these criteria were used were evaluated for 1,267 
consecutive patients given thrombolytic therapy. 
Twenty-five community hospitals and 7 interverr 
tional centers were the sites of enrollment. Most 
patients (62%) were enrolled from community hoe 
pitals. Criteria for thrombolytic therapy included: 
symptoms of acute myocardial infarction c6 hours 
but ~20 minutes, and not relieved by nitroglycerin; 
and S’kegment elevation ri mm in 2 contiguous 
leads or ST-segment depression of posterior my- 
ocardial infarction. Exclusion criteria reflecting ir+ 
creased risk of bleeding were used. A final diag- 
nosis of myocardial infarction was based on creat- 
inine kin-MB, electrocardiographic and ven- 
triculographic evaluation. Acute myocardial infarc- 
tion was misdiagnosed in 20 patients (1.4%; 95% 
confidence interval O&2.0%). These patients 
were demographically similar to those with acute 
myocardial infarction. All misdiagnosed patients 
survived; no significant adverse events occurred. 
Thus, in several clinical settings, a simple alge 
rithm with specific criteria was used for diw 
ing acute myocardial infarction and administering 
thrombolytic therapy. The inclusion criteria used 
in this study led to a low rate of misdiagnosis. 
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T hrombolytic therapy is standard care in treating acute myocardial infarction in appropriately se- lected patients. l Well-controlled studies have 
proved its role in restoring vessel patency, improving left 
ventricular function and decreasing mortality.2-7 Despite 
these benefits, apprehension for its complications may 
limit its use. Infrequent but major bleeding complica- 
tions8 raise concern, especially in patients with a mis- 
taken diagnosis of acute myocardial infarction. Reports 
of the disastrous consequences of thrombolytic therapy 
to patients with aortic dissection or hemorrhagic peri- 
carditis reinforce this issue.8,9 
Given the high incidence and multiple etiologies of 
chest pain, and the need to administer thrombolytics 
early in the course of infarction, a mistaken diagnosis 
with inappropriate treatment could be extremely fre- 
quent. Misdiagnosis rates for acute myocardial infarction 
as great as 41% have been reported when electro- 
cardiographic criteria are not used.‘O However, electro- 
cardiographic criteria alone may be insufficient. Lee et 
al” found that approximately 25% of patients who pre- 
sented with acute chest pain and ST elevation did not 
have myocardial infarction. 
In addition, most patients with suspected acute in- 
farction are evaluated by primary care physicians with- 
out specialized training in cardiovascular medicine. The 
primary care physician may be less comfortable than 
a cardiologist in making the diagnosis and initiating 
thrombolytic therapy. Therefore, specific criteria for pa- 
tient enrollment in community hospitals were developed 
by the Thrombolysis and Angioplasty in Myocardial In- 
farction (TAMI) study group (see later). These criteria 
were used in several different clinical settings, primari- 
ly by physicians who are not cardiovascular specialists. 
The purpose of this study was to evaluate the incidence 
and outcomes of misdiagnosis of acute myocardial in- 
farction for patients given thrombolytic therapy in our 
series of 5 multicenter trials. 
Ml3HODS 
Criteria for patient selection: Patients enrolled in 
the TAMI- 1,2 and 3, Intravenous Urokinase and TAMI- 
5 thrombolytic trials were evaluated for contirmation of 
myocardial infarction. The protocols for these studies, 
which were approved by institutional review boards at 
each facility and required informed consent for patient 
participation, were published previously.12-16 Patients 
were considered for inclusion if they had symptoms of 
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TABLE I Characteristics of Acute Myocardial Infarction 
Patients Versus Misdiagnosed Patients 
AMI No AMI 
(n = 1,367) (n = 20) 
Age (year) 56.9 f 10.2 51.6 2 10.6 
25th, 50th, 75th percentiles 50, 58, 65 42, 51, 59 
Men 1,080 (79%) 14 (70%) 
Systemic hypertension* 588 (43%) 2 (10%) 
Hyperlipidemiat 260 (19%) 4 (20%) 
Family Hx of cardiovascular 725 (53%) 10 (50%) 
disease 
Hx of smoking 848 (62%) 12 (60%) 
Diabetes 219 (16%) 1 (5%) 
Previous AMI 178 (13%) 3 (15%) 
Peripheral vascular disease 68 (5%) 0 
Heart rate (beats/min) 78 t- 18 82 + 15 
25th, 50th, 75th percentiles 64, 76,88 71, 79,95 
Systolic BP (mm Hg) 132 i. 24 140 ? 26 
25th, 50th, 75th percentiles 114,130, 148 122,130, 161 
Diastolic BP (mm Hg) 82 k 17 88 + 21 
25th, 50th, 75th percentiles 70, 81, 92 77, 84, 98 
Rales 259 (19%) 2 (10%) 
S3 gallop 41 (3%) 1 (5%) 
Duration of chest pain before 181 2 87 191 k 65 
thrombolytic Rx (min) 
25th, 50th, 75th percentiles 130, 174,223 129,213,244 
Peak CK (IUIL) 1,943 2 2,255 80.7 k 50.8 
25th, 50th, 75th percentiles 685, 1,518, 2,500 47,62,103 
Peak CK-MB (IU/L) 243 + 523 4.8 2 3.5 
25th, 50th, 75th percentiles 49,108,234 0.9, 5.7, 7.2 
*Patients previously diagnosed with systemic hypertension. 
tSerum cholesterol 2240 mgldl, low-density lipoprotein cholesterol 2 160 mg/dl 
)r triglycerides > 500 mgidl. 
AMI = acute myocardial infarction; BP = blood pressure; CK = creatlne kinase; 
ix = history: Rx = therapy. 
acute myocardial infarction for <6 hours but >20 min- 
utes after onset. Patients who had prompt relief of symp- 
toms with sublingual nitroglycerin were excluded. Elec- 
trocardiographic criteria were the presence of ST-seg- 
ment elevation 21 mm in 2 contiguous leads or ST 
depression consistent with posterior infarction, in the 
absence of previous Q-wave infarction in the same 
infarct-related artery distribution. Patients aged >75 
years, and those with a recent history of cerebrovascu- 
lar disease, surgery, trauma, bleeding or coronary artery 
bypass grafting were excluded. Patients with significant 
hypertension (>lSO mm Hg systolic or >llO mm Hg 
diastolic) or hypotension (~80 mm Hg systolic not re- 
sponsive to fluid resuscitation) were also excluded. 
These spectic criteria were used in 25 community hos- 
pitals and 7 interventional centers to enroll 1,387 pa- 
tients; a complete listing of these hospitals was present- 
ed previously.12 
Determination of myocardial infarction: The 
attending cardiologist at each interventional center deter- 
mined the iinal diagnosis for each patient based on cre- 
atinine kinase (CK)-MB, electrocardiographic and ven- 
triculographic evaluation in the setting of a compatible 
clinical event. Values for significant CK-MB elevation 
that were standard for each center were used and re- 
corded prospectively. The entry electrocardiogram was 
sent to the ECG Coordinating Center at Duke Universi- 
ty Medical Center for analysis. Angiographic data were 
used where appropriate (e.g., unstable angina was diag- 
nosed if significant coronary artery stenosis was noted 
and if no increase in CK-MB was detected). 
Identification of patients misdiagnosed with 
myocardial infarction: Patients were identified in a 
prospective fashion by the diagnosis given during their 
hospitalization. In addition, the records for any patient 
with a coronary angiogram showing an infarct-related 
artery stenosis ~75% were reviewed for misdiagnosis of 
acute infarction. 
Angiographic interpretation: All coronary angio- 
grams were reviewed by the clinical stti at each insti- 
tution in conjunction with the clinical diagnosis. Each 
coronary angiogram was then forwarded and indepen- 
dently evaluated at the University of Michigan Core 
Angiographic Laboratory. Left ventricular ejection frac- 
tion and the degree of coronary artery stenosis were 
assessed at the core laboratory as previously de- 
scribed.‘*J7J8 The core laboratory values were used for 
data review and analysis. 
Determination of clinical outcomes: The major 
outcomes assessed in this study were death, nonhemor- 
rhagic stroke, intracranial bleed, blood loss (needing 
transfusion of 22 units of packed red blood cells), sus- 
tained hypotension and vascular repair of a catheteriza- 
tion site. Patients were carefully monitored throughout 
hospitalization. Multiple data items were collected 
prospectively by research nurses during the patients’ 
clinical courses. The findings were forwarded to the 
Biostatistical Coordinating Center at Duke University 
Medical Center for data entry and quality assurance. All 
major outcomes were checked against the medical 
record. In addition, any documentation of the use of 
cocaine or alcohol, the occurrence of cardiac tampon- 
ade, or any other complication related to receiving 
thrombolytic therapy in the misdiagnosed group was 
assessed by reviewing medical records retrospectively. 
Data analysis: Data are expressed as mean ? 1 SD, 
and as 25th, 50th and 75th percentiles for each group. 
A binomial distribution of dichotomous events was as- 
sumed for determining confidence intervals.19 A chi- 
square test was used to compare misdiagnosis rates be- 
tween referral centers and community hospitals. 
RESULTS 
Percentage of study group misdiagnosed with 
acute myocardial infarction: Of 1,387 patients en- 
rolled, 20 (1.4%; 95% confidence interval 0.X-2.0%) had 
no evolutionary evidence of acute myocardial infarction 
despite entry in the trial. Nonischemic chest pain syn- 
dromes in conjunction with early repolarization were 
observed in 4 patients; 1 with probable esophageal 
spasm presented with inferior ST elevation. Pericarditis 
(n = 3), vasospasm (n = 3), hypertensive cardiomyopathy 
(n = 1) and unstable angina (n = 8) were the diagnoses 
for 15 patients. The rates of misdiagnosis for the 5 tri- 
als were as follows: 1% (4 of 386) for TAMI-1, 1.4% 
(1 of 147) for TAMI-2, 1.7% (3 of 175) for TAM13, 
2.9% (3 of 102) for the Intravenous Urokinase trial, and 
1.4% (8 of 577) for TAMI-5. Community hospitals 
enrolled 63% of patients. Fifteen misdiagnosed patients 
were in this subgroup, resulting in a misdiagnosis rate 
for community hospitals of 1.7% (15 of 874). The re- 
maining 5 misdiagnosed patients were initially evaluat- 
ed in 1 of 7 tertiary hospitals, resulting in a misdiagno- 
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sis rate for referral centers of 1% (5 of 513). The slight- group. The misdiagnosed group tended to be younger 
ly greater misdiagnosis rate for community hospitals and had a lower incidence of history of hypertension; 
was not statistically significant (p = 0.26). however, there were no differences for cardiovascular 
Cheractektics of patienb with myocardii infarc- disease risk factors. Likewise, no difference was detect- 
tion versus misdiagnosed patients: Table I shows ed between the groups at presentation for heart rate, 
historical, clinical and cardiac enzyme data for the study blood pressure, presence of rales or Ss gallop, or in the 
FIGURE 1. Top, entry elee 
trecardiogram from patient 
with no coronary artery dis- 
ease at catheterization, with 
final diagnosis of coronary 
vawspasm. Middle, entry 
electrocardiogram from pb 
tient with final diagnosis of 
left ventricular hypertrophy. 
Bottom, entry electrocardi* 
gram from patient with no 
coronary artery disease at 
catheterization, with final di- 
agnosis of benign ST elevs+ 
tion/early repolarization. 
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duration of chest pain before receiving thrombolytic 
therapy. 
Figure 1 shows electrocardiograms from patients 
given thrombolytic therapy and subsequently diagnosed 
with coronary vasospasm, pericarditis and early repolar- 
ization. On review of the 20 entry electrocardiograms 
for the misdiagnosed group, 11 (55%) did not fulfill the 
electrocardiographic criteria of 21 mm of ST elevation 
in 2 contiguous leads or ST depression consistent with 
posterior infarction, with absence of Q waves in the area 
of injury. 
Coronary angiograms were obtained in 17 of 20 mis- 
diagnosed patients (85%) and in 1,316 of 1,367 patients 
(96%) with acute infarction. No difference in left ven- 
tricular ejection fraction was observed between the 2 
groups (acute infarction patients 51 + 12% vs misdiag- 
nosed patients 48 IfI 14%; p = NS). In the misdiagnosed 
group, 8 patients had no coronary artery stenoses 250%; 
3 had l-vessel disease, 3 had 2-vessel disease, and 3 
patients had 3-vessel disease. 
Retrospective review of the records of the misdiag- 
nosed group revealed no evidence of cocaine use, alco- 
hol intoxication or other substance abuse in the 20 
patients. 
Outcomes for patients Patients with acute infarc- 
tion in this study had complication rates of 6% for death, 
1.5% for nonhemorrhagic stroke, 1% for intracranial 
bleed, 17% for bleeding needing transfusion of 22 units 
of packed red blood cells, and 2% for surgical repair of 
the catheterization site; no patient in the misdiagnosed 
group (95% contidence interval 0 to 14%) had any of 
these complications. l9 No incidences of cardiac tam- 
ponade, aortic dissection, complications of central line 
placement, or other major iatrogenic complications were 
observed. One patient developed a large hematoma at a 
peripheral intravenous site, 2 developed transient hema- 
turia after placement of a urethral catheter, and 1 expe- 
rienced chills with administration of urokinase. 
One patient in the misdiagnosed group with 3-vessel 
coronary artery disease developed refractory unstable 
angina and needed urgent coronary bypass surgery. This 
patient received 3 units of packed red blood cells in the 
perioperative period. Two other patients in the misdi- 
agnosed group with unstable angina underwent angio- 
plasty procedures without complication. Two additional 
patients eventually needed elective coronary bypass sur- 
gery. 
DISCUSSION 
The major findings of this study were as follows: (1) 
The incidence of misdiagnosis of acute myocardial in- 
farction was quite low when specific historical, clinical 
and electrocardiographic criteria were used; and (2) the 
use of clinical and electrocardiographic criteria such as 
ours may reduce the risk of serious bleeding in patients 
who are misdiagnosed, no deaths or significant untoward 
events occurred. 
Careful attention to the electrocardiogram is under- 
scored in this study; 55% of patients (11 of 20) misdiag- 
nosed had a nondiagnostic entry electrocardiogram. Tii- 
als using more permissive criteria than those of this 
study for administering thrombolytic therapy have been 
completed. In Gruppo Italiano per lo Studio della Strep- 
tochinasi nell’Infarcto Miocardico (GISSI),5 patients 
were not excluded if a Q wave was observed in the area 
of injury; patients were also enrolled for ST depression 
in the limb leads. The misdiagnosis rate was 5.8%. The 
Anglo-Scandinavian Study of Early Thrombolysis 
(ASSET) enrolled 2,516 patients based on the clinical 
decision of the physician treating the patient, and the 
percentage of patients misdiagnosed was 10.5%.6 The 
Thrombolysis Early in Acute Heart Attack Trial (TEA- 
HAT)‘O enrolled 352 patients with suspected acute in- 
farction within 165 minutes of chest pain without re- 
quiring electrocardiographic criteria; a misdiagnosis rate 
of 41% was observed. Thus, in our study with the use 
of specific electrocardiographic criteria in addition to 
historical and clinical criteria, a misdiagnosis rate of 
1.4% compares very favorably. 
Did this lower incidence of mistaken diagnosis ac- 
count for the absence of major adverse consequences in 
patients misdiagnosed for acute myocardial infarction? 
In ASSET, patients with suspected infarction were giv- 
en recombinant tissue plasminogen activator; 5 aortic 
dissections from the cohort of 2,516 patients were rec- 
ognized in the lirst 24 hours and were fatal within 48 
hours, and 2 dissections were discovered later during the 
hospital stay.6,20 No aortic dissections were observed in 
our study. This could be due to the more restrictive elec- 
trocardiographic changes required. It could also be due 
to chance alone, with an incidence of aortic dissection 
in the United States of approximately 0.03% yearly.*l 
However, patients with aortic dissection may have clini- 
cal presentations imitating myocardial infarction,22 and 
the more specific criteria may have conferred a diagnos- 
tic and survival benefit. Furthermore, in ASSET, among 
patients in whom a nonischemic chest pain syndrome 
was finally diagnosed, those treated with thrombolytic 
therapy had a 9.5% mortality rate compared with 1.2% 
for those treated with placebo.9 Thus, the absence of 
more specific criteria may have contributed to patients 
with other conditions (e.g., pericarditis and gastro- 
intestinal disease) receiving thrombolytic therapy and 
having adverse consequences.9,23-25 
The small number of patients in the misdiagnosed 
group limits the ability to demonstrate absence of ad- 
verse effects. No major complication in 20 patients has 
a wide confidence interval (0 to 14%).19 A study with a 
larger number of misdiagnosed patients would give 
greater power to the analysis of complication rates. For 
example, at a power of 80% and alpha of 0.05, a total 
of 125 misdiagnosed patients would be needed to detect 
a 5% complication rate. The small number of misdiag- 
nosed patients in our cohort weakens the ability to state 
that patients inappropriately given thrombolytic therapy 
using our inclusion criteria have no or few adverse out- 
comes. Studies with larger numbers of misdiagnosed pa- 
tients will be able to better comment on complication 
rates, but will also need to be interpreted in regard to 
the inclusion criteria used (lax vs strict). 
An issue in any study assessing misdiagnosed pa- 
tients given thrombolytic therapy is that the treatment 
may abort a potential myocardial infarction by achiev- 
ing clot lysis and reperfusion before myocardial necro- 
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sis occurs. In this study, 20 patients had no evidence of 
acute myocardial infarction based on ventriculogram, 
cardiac enzymes and evolutionary changes in the elec- 
trocardiogram. Of these patients, 9 had underlying cor- 
onary artery disease at catheterization. Eight patients had 
normal coronary arteries or insignificant coronary artery 
disease. Three patients in the misdiagnosed group did 
not have catheterization. Thus 20 of 1,387 patients could 
have lysed thrombus before progression to infarction. 
All patients in this group survived, but the numbers are 
too small to make conclusions regarding the benefit of 
thrombolytic therapy to patients with unstable angina. 
No large, randomized, controlled trial has been reported 
to evaluate whether thrombolytic therapy is beneficial 
for patients with unstable angina.26 
The role of thrombolytic therapy in the treatment of 
patients with acute myocardial infarction continues to 
develop. The criteria used for inclusion in this study may 
prove to be too restrictive. Cragg et al27 reviewed 1,471 
patients with acute myocardial infarction who presented 
to a large, community-based hospital; only 230 (16%) 
were eligible for thrombolytic therapy under protocol 
criteria similar to those in our study. Lee et all’ evalu- 
ated 7,734 patients presenting to the emergency wards 
of 3 university and 4 community hospitals; 1,118 were 
ultimately shown to have acute infarction. Of these 
patients, 41% would have mhilled electrocardiographic 
criteria similar to those used in our study. If other crite- 
ria were used (chest pain <6 hours and bleeding risk fac- 
tors) this percentage would decrease to 25%.25 Many 
patients with acute infarction who do not f&ill the cri- 
teria of our study may benefit from thrombolytic thera- 
py. The results from ISIS-24 suggest that infarcting 
patients may benefit from treatment with thrombolytic 
therapy up to 24 hours after the onset of chest pain. 
ISIS-2 also suggests that patients aged >75 years may 
have substantial benefit from thrombolytic therapy, with 
mortality in this group reduced from 13 to 9%.4,28 In 
ASSET, trends toward survival benefit were observed in 
all groups, including those who had normal electrocar- 
diograms6 The results from on-going clinical trials, as 
well as future developments in biochemical tests and 
noninvasive modalities for early diagnosis, should better 
clarify which patients to treat with thrombolytic therapy 
in the setting of acute myocardial infarction.28-30 
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